drugset / Trial / NCT02036255

Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase

NCT02036255 ↗

Phase 3 Completed 68 enrolled University Hospital Brussels
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of our study is to investigate whether the substitution of the standard locking solution with a locking solution containing taurolidine and urokinase weekly (Taurolock ™ U 25,000 - www.taurolock.com ) reduces the rate of catheter dysfunction in hemodialysis patients with a history of TCC dysfunction requiring urokinase therapy.

Timeline

Start
2015-05
Primary completion
2017-07
Completion
2018-05

Outcome

Met primary endpoint

paper Incidence rate of thrombotic catheter dysfunction was 4.8 in TaurolockU vs 12.1/1000 catheter days in control group (rate ratio 0.39; 95%CI 0.23-0.64). PMID 34015014 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Heparin Other / unclassified 500 iu Other
Subject Urokinase Protein / enzyme biologic 25000 unknown Other
Background taurolidine Small molecule — Other

Indications